April 12, 2021 4:57pm

The sector is what it is, until it isn’t and even then, it doesn’t seem to be … as “our” universe runs out of buyers, it runs into trouble (just like a fire that runs out of wood).

Pre-open indication results: 8 HITs and 1 Miss

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing! 

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors

The Dow closed DOWN -55.20 points (- 0.16%); the S&P closed DOWN -0.81 points (-0.02 %) while the Nasdaq closed DOWN -50.19 points (0.36%)



As I have stated new market highs always to me the say … bye!

Indexes fell slightly from record levels on Monday as muted trading resumed before Q1 earnings’ season and the release of widely-watched inflation data.

Market volatility has declined to pre-pandemic levels amid rising reopening optimism. The Cboe Volatility Index, AKA the VIX or the market’s fear gauge, has traded below 18 for the past four days, a level unseen since February 2020. <CNBC>


RegMed Investors’ (RMi) pre-open: “caution is in the air as the trend indicator beguiles.” … https://www.regmedinvestors.com/articles/11860     


Pre-open indication results:  8 HITs <Maintain SELL: Biostage (BSTG -$0.08 to $1.17 with 3,631 shares traded – the “pumping” is back to supplement further declines): BUY: Editas Medicine (EDIT +$0.05), ReNeuron (RENE.L +$4.50); SELL: Athersys (ATHX -$0.04), MiMedx (MDXG -$0.31), CRISPR Therapeutics (CRSP -$1.35), Intellia Therapeutics (NTLA -$2.23), Verastem (VSTM -$0.19)> and 1 MISS < Vericel (VCEL +$0.41)>


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Monday opened negative at 5/28, 1 flat and 1 acquired, stayed negative at the mid-day to 5/29, and 1 acquired, closing negative at 4/30 and 1 acquired;


There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

  • ReNeuron (RENE.L), Editas Medicine (EDIT), Vericel (VCEL), Sangamo Therapeutics (SGMO), to name 4 of the 4 inclining of the 35 covered

Hammered in today’s market:

  • Alnylam Pharmaceuticals (ALNY), Fate Therapeutics (FATE), Ultragenyx (RARE), Intellia Therapeutics (NTLA), Sage Therapeutics (SAGE), to name 5 of the 30 declining of the 35 covered


Key metrics:

  • Sector volume had LOW with 1 of the 4-upside having higher than the 3-month average volume with the volume of 6 of 30-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 4-upside were +0.13% (EDIT) to +3.38% (RENE.L) while the 30-downside ranges from -0.11% (ADVM) to -9.66% (CLBS);


Monday’s (4 of 4) incline

  • ReNeuron (RENE.L +$4.50 after Friday’s +$12.00);
  • Vericel (VCEL +$0.41 after Friday’s -$2.05);
  • Editas Medicine (EDIT +$0.05 after Friday’s -$1.30);
  • Sangamo Therapeutics (SGMO +$0.04);

Monday’s (10 of 30) decliners:

  • Alnylam Pharmaceuticals (ALNY -$3.20 after Friday’s -$4.27);
  • Fate Therapeutics (FATE -$2.99 after Friday’s -$1.02
  • Ultragenyx (RARE -$2.95 after Friday’s -$3.07);
  • Intellia Therapeutics (NTLA -$2.23 after Friday’s -$2.44
  • Sage Therapeutics (SAGE -$1.93);
  • Ionis Pharmaceuticals (IONS -$1.49);
  • Regenxbio (RGNX -$1.42);
  • CRISPR Therapeutics (CRSP -$1.35 after Friday’s -$4.64
  • Cellectis SA (CLLS -$1.26);
  • Chinook Therapeutics (KDNY -$1.22 after Friday’s +0.44)

Closing: 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19:

  • Dr. Scott Gottlieb said that Americans having digital access to their Covid vaccination status would be helpful in navigating the coronavirus pandemic in the months ahead. <CNBC>

COVID Data Tracker <Million>:

  • Monday 30.965 M cases,
  • Monday’s death rate totaled 558,843 <Johns Hopkins University>
  • Monday vaccinations: 187 M



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -1.50% and XBI closed down -1.99%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.22 points or +1.32% at 16.91

Upside volume: low

  • Monday: 1 out of the 4-upside had higher than the 3-month average volume;

Downside volume: low

  • Monday: 6 out of the 30-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Monday’s percentage (%) of the 4-upside were +0.13% (EDIT) to +3.38% (RENE.L) while the 30-downside ranges from -0.11% (ADVM) to -9.66% (CLBS);


April, the beginning of Q2/21:

Monday (4/12) closed negative with 4 advancers, 30 decliners and 1 acquired

Friday closed negative with 5 advancers, 26 decliners, 3 flats and 1 acquired


The BOTTOM LINE: Another downslide as sector momentum remains “sketchy” and these depressed pricing guarantees more uncertainty and risks but, some rebounds.

NEWS, clinical – non-financial (i.e., raising capital) needs to flow!!!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

Don’t get complacent …


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.